Search Results for "Innovation"

A closer look at three of PhRMA’s most cited talking points.

Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.

Dr. Peter Bach joins Innovation Hub Radio by WGBH to discuss how incentives provided through policies have rewarded innovation for rare drugs and whether these are the right national healthcare priorities today.

The ability to charge high prices is only one component of a complex system of risks and rewards that underlies pharmaceutical innovation.

Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.

Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.

To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.

Dana Goldman and Darius Lakdawalla look to Major League baseball to explain the drug pricing problem.

Drug prices have taken center stage since Turing Pharmaceuticals raised the price of its off-patent parasite-fighting drug Daraprim by over 5,000%.

When Martin Shkreli of Turing Pharmaceuticals raised the price for Daraprim by 5,455%, he put drug pricing on the agenda for the leading 2016 presidential candidates.

When anyone proposes reducing prescription drug prices— as Hillary Rodham Clinton and Bernie Sanders recently have—the most commonly heard criticism is that it would squelch innovation.

After Turing Pharmaceuticals raised the price of a drug from $13 a pill to $750, two leading Democratic candidates for president are proposing big changes. On PBS NewsHour, Dr. Bach provides one view on the situation.

Dr. Bach describes how the ability to charge increasingly higher prices for drugs that already have competition on the market is stifling innovation and wasting resources and human subjects.

In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.

Industry leaders argue that high prices are necessary for innovation, but just how high do prices need to be?

Medicare must find new ways to achieve cost control without limiting access to beneficial services.